Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
412 studies found for:    myelodysplastic syndromes | Open Studies
Show Display Options
Rank Status Study
21 Recruiting The National Myelodysplastic Syndromes (MDS) Study
Condition: Myelodysplastic Syndromes (MDS)
Intervention: Other: Therapeutic
22 Recruiting Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Interventions: Procedure: Best Supportive Care;   Drug: BI 836858
23 Recruiting A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Intervention: Drug: OPN-305
24 Recruiting CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy
Condition: Previously Treated Myelodysplastic Syndromes
Intervention: Drug: 6,8-bis(benzylthio)octanoic acid
25 Recruiting Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
Condition: Myelodysplastic Syndromes
Interventions: Drug: Talacotuzumab;   Drug: Daratumumab
26 Recruiting A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy.
Condition: Myelodysplastic Syndrome
Interventions: Procedure: Bone marrow aspirate;   Drug: Deferasirox
27 Recruiting Entinostat and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome After DNMTi Therapy Failure
Condition: Previously Treated Myelodysplastic Syndrome
Interventions: Drug: Entinostat;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
28 Recruiting A Safety and Pharmacology Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Interventions: Drug: Atezolizumab;   Drug: Azacitidine
29 Recruiting Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.
Conditions: Adult Patients With Low Risk Myelodysplastic Syndrome;   Adult Patients With Int 1-risk Myelodysplastic Syndrome
Interventions: Drug: Erythropoietin alpha;   Drug: Deferasirox
30 Not yet recruiting Azacitidine and Pembrolizumab for Patients With Myelodysplastic Syndrome (MDS)
Conditions: Hematopoietic/Lymphoid Cancer;   Myelodysplastic Syndrome
Interventions: Drug: Azacitidine;   Drug: Pembrolizumab
31 Recruiting Efficacy of Eltrombopag Plus Lenalidomide Combination Therapy in Patients With IPSS Low and Intermediate-risk Myelodysplastic Syndrome With Isolated del5q
Condition: Myelodysplastic Syndromes
Interventions: Drug: Eltrombopag/Revolade;   Other: Placebo;   Drug: Lenalidomide
32 Recruiting A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)
Conditions: Myelodysplastic Syndromes;   Thrombocytopenia
Intervention: Drug: Eltrombopag
33 Not yet recruiting CB-839 + Azacitidine for Treatment of Myelodysplastic Syndrome (MDS)
Conditions: Myelodysplastic Syndrome;   Other Diseases of Blood and Blood-forming Organs
Interventions: Drug: CB-839;   Drug: Azacitidine
34 Recruiting Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant
Conditions: Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Secondary Myelodysplastic Syndrome
Interventions: Drug: Azacitidine;   Drug: Decitabine;   Other: Quality-of-Life Assessment
35 Recruiting The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)
Condition: Myelodysplastic Syndrome
Interventions: Drug: Oral Azacitidine;   Drug: Placebo
36 Recruiting A Prospective, Multicentre European Registry for Newly Diagnosed Patients With Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes (MDS)
Intervention: Other: No interventions
37 Recruiting Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
Conditions: Myelodysplastic Syndromes;   Acute Myeloid Leukemia;   Chronic Myelomonocytic Leukemia
Intervention: Drug: H3B-8800
38 Recruiting Efficacy and Safety of Ultra Small Dose Decitabine for the Lower Risk MDS Patients With Transfusion Dependent
Condition: Myelodysplastic Syndromes
Intervention: Drug: decitabine
39 Recruiting Safety & Pharmacokinetics of Pegolsihematide for Treatment of Anemia Patient With Myelodysplastic Syndromes
Conditions: Myelodysplastic Syndromes;   Anemia
Intervention: Drug: Pegol-sihematide injection
40 Not yet recruiting Pyrimethamine for Intermediate/High-risk Myelodysplastic Syndromes (MDS) That Has Relapsed or Refractory to Azanucleosides
Condition: Myelodysplastic Syndromes
Intervention: Drug: Pyrimethamine

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.